Eleven Biotherapeutics announces pricing of $10.0 million offering priced at-the-market
Eleven Biotherapeutics announced that it has entered into a definitive agreement with several institutional and accredited investors for the purchase of 7,968,128 shares of its common stock, at a purchase price per share of $1.13, for gross proceeds of $9.0 million. March 21, 2018